Is Agios Pharmaceuticals, Inc. overvalued or undervalued?

As of 13 August 2025, Agios Pharmaceuticals, Inc. has moved from a fair to attractive valuation grade. The company appears to be undervalued, evidenced by a P/E ratio of 4, a PEG ratio of 0.01, and an EV to EBITDA of -3.81. In comparison to peers, PTC Therapeutics, Inc. has a P/E of 5.85 and Crinetics Pharmaceuticals, Inc. shows a negative P/E of -8.95, indicating that Agios is positioned favorably within its industry.
While Agios has shown a year-to-date return of 15.49%, outperforming the S&P 500's 12.22%, its one-year return of -16.67% lags behind the index's 17.14%. This mixed performance highlights the potential for recovery, aligning with its attractive valuation.